X0306 4/A 2015-04-14 2015-04-14 0 0001348911 Carbylan Therapeutics, Inc. CBYL 0001469547 Vivo Ventures VI, LLC C/O VIVO CAPITAL LLC 575 HIGH STREET, SUITE 201 PALO ALTO CA 94301 0 0 1 0 0001469473 Vivo Ventures Fund VI, L.P. 575 HIGH STREET, SUITE 201 PALO ALTO CA 94301 0 0 1 0 0001400245 VIVO VENTURES VI AFFIILATES FUND, L.P. 575 HIGH STREET, SUITE 201 PALO ALTO CA 94301 0 0 1 0 Common Stock 2015-04-14 4 C 0 2476452 A 2476452 I See Footnotes Common Stock 2015-04-14 4 C 0 18140 A 2494592 I See Footnotes Common Stock 2015-04-14 4 C 0 387960 A 2882552 I See Footnotes Common Stock 2015-04-14 4 C 0 2842 A 2885394 I See Footnotes Common Stock 2015-04-14 4 C 0 304438 A 3189832 I See Footnotes Common Stock 2015-04-14 4 C 0 2230 A 3192062 I See Footnotes Common Stock 2015-04-14 4 P 0 1005136 5.00 A 4197198 I See Footnotes Common Stock 2015-04-14 4 P 0 7364 5.00 A 4204562 I See Footnotes Series B Convertible Preferred Stock 2015-04-14 4 C 0 2476452 D Common Stock 2476452 0 I See Footnote Series B Convertible Preferred Stock 2015-04-14 4 C 0 18140 D Common Stock 18140 0 I See Footnote Convertible Promissory Note 2015-04-14 4 C 0 387960 D Common Stock 387960 0 I See Footnote Convertible Promissory Note 2015-04-14 4 C 0 2842 D Common Stock 2842 0 I See Footnote Convertible Promissory Note 2015-04-14 4 C 0 304438 D Common Stock 304438 0 I See Footnote Convertible Promissory Note 2015-04-14 4 C 0 2230 D Common Stock 2230 0 I See Footnote Upon the closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one for one basis without payment or further consideration, and has no expiration date. The reported shares are held directly by Vivo Ventures Fund VI, L.P. ("VIF"). Vivo Ventures VI, LLC ("Vivo LLC") is the general partner of VIF. As such, Vivo LLC may be deemed to be the beneficial owner of the shares held directly by VIF. The managers of Vivo LLC include Frank Kung, Edgar Engleman, and Albert Cha. Accordingly, each Frank Kung, Edgar Engleman and Albert Cha may be deemed to be the beneficial owner of the shares held directly by VIF. Each of Vivo LLC, Frank Kung, Edgar Engleman and Albert Cha disclaims beneficial ownership of the securities held by VIF, except to the extent of such individual's or entity's pecuniary interests in the securities. The reported shares are held directly by Vivo Ventures VI Affiliates Fund, L.P. ("VIAF"). Vivo Ventures VI, LLC ("Vivo LLC") is the general partner of VIAF. As such, Vivo LLC may be deemed to be the beneficial owner of the shares held directly by VIAF. The managers of Vivo LLC include Frank Kung, Edgar Engleman, and Albert Cha. Accordingly, each Frank Kung, Edgar Engleman and Albert Cha may be deemed to be the beneficial owner of the shares held directly by VIAF. Each of Vivo LLC, Frank Kung, Edgar Engleman and Albert Cha disclaims beneficial ownership of the securities held by VIAF, except to the extent of such individual's or entity's pecuniary interests in the securities. The Convertible Promissory Note is convertible into the number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing the entire principal amount and 184 days of accrued interest on the Convertible Promissory Note by 80% of the initial public offering price of $5.00 per share of the Issuer's Common Stock, automatically upon the closing of the Issuer's initial public offering, and has no expiration date. The Convertible Promissory Note is convertible into the number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing the entire principal amount and 41 days of accrued interest on the Convertible Promissory Note by 80% of the initial public offering price of $5.00 per share of the Issuer's Common Stock, automatically upon the closing of the Issuer's initial public offering, and has no expiration date. The number of shares in Column 5 represents the aggregate number of shares directly beneficially owned by both VIF and VIAF. Vivo LLC, the Designated Reporting Person, is the general partner of both VIF and VIAF. By: /s/ Albert Cha, M.D., Ph.D., Managing Member of Vivo Ventures VI, LLC, the General Partner of Vivo Ventures VI Fund L.P. and Vivo Ventures VI Affiliates Fund, L.P. 2015-04-24